Research report

Dopamine is differentially involved in the locomotor hyperactivity produced by manipulations of opioid, GABA and glutamate receptors in the median raphe nucleus

Insop Shim,a, b Thomas R. Stratforda, David Wirtshaftera,∗

a Department of Psychology, University of Illinois at Chicago MC 285 1007 W. Harrison St., Chicago 60607-7137, IL, U.S.A
b AMSRC, Department of Basic Science College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Korea

HIGHLIGHTS
• We studied effects of haloperidol on median raphe nucleus (MR) induced-hyperactivity.
• Glutamate antagonist pBB-PZDA in MR induced haloperidol insensitive hyperactivity.
• GABA agonists muscimol and baclofen induced haloperidol insensitive hyperactivity.
• Opioid agonists DAMGO and DPDPE induced haloperidol sensitive hyperactivity.
• The effects of different drugs injected in MR are mediated through different pathways.

ARTICLE INFO

Article history:
Received 17 September 2013
Received in revised form
30 November 2013
Accepted 2 December 2013
Available online 12 December 2013

Keywords:
Locomotion
Hyperlocomotion
Tegmentum
Nucleus centralis superior
Dopaminergic
RMTg

ABSTRACT

The median raphe nucleus (MR) has been shown to exert a powerful influence on behavioral arousal and marked locomotor hyperactivity can be produced by intra-MR injections of a variety of drugs including GABAa and GABAb agonists, excitatory amino acid antagonists, and μ- and δ-opioid agonists. Other studies have indicated that the MR exerts an inhibitory influence on ascending dopaminergic transmission, suggesting that MR induced alterations in activity may be mediated through changes in dopaminergic transmission. In the present study, we explored this possibility by examining whether systemic administration of the preferential D2 dopamine antagonist haloperidol is able to antagonize the hyperactivity produced by intra-MR injections of various drugs. We found that haloperidol completely blocked the locomotor response to intra-MR injections of the μ-opioid receptor agonist DAMGO and the δ-opioid receptor agonist DPDPE. In marked contrast, at doses which abolished the locomotor response to systemic amphetamine, haloperidol had no effect on the hyperactivity induced by intra-MR injections of GABAa agonist muscimol, the GABAb agonist baclofen, or the kainate/quisqualate antagonist pBB-PZDA, even though it suppressed baseline activity in these same animals. These results indicate that there must be at least two mechanisms capable of influencing behavioral arousal within the MR region, one of which is dependent on D2 dopamine receptors and the other is not.

© 2013 Elsevier B.V. All rights reserved.

The mesencephalic median raphe nucleus (MR) is known to exert a major influence on locomotor activity. For example, marked increases in locomotion are seen after either electrolytic or excitotoxic lesions of the MR [1–5], and even more dramatic effects can be observed after intra-MR injections of a variety of drugs, including GABAa and GABAb agonists, excitatory amino acid (EAA) antagonists, and μ- and δ-opioid agonists [6–10]. These responses are, in general, much larger when the drugs are injected into the MR than when they are applied to surrounding structures [6–8,11], suggesting that their effects are exerted within the immediate vicinity of the MR, rather than through diffusion to distant structures. Even though the MR is one of the major sources of serotonergic projections to the forebrain, the majority of cells in this nucleus utilize transmitters other than serotonin [12], and several lines of evidence indicate that influence of the MR on activity is largely mediated through nonserotonergic mechanisms [2,9,13].

While the pathways through which the MR exerts its dramatic effects on locomotion remain to be identified, one interesting possibility is suggested by the observation that the MR sends a projection to the ventral tegmental area (VTA) [14–16], the origin of ascending dopaminergic projections to the nucleus accumbens and olfactory tubercle. Further, it has been shown that dopamine turnover in the nucleus accumbens can be increased by intra-MR injections of GABAa, GABAb, μ- and δ-opioid receptor agonists, as...
well as by injections of EAA antagonists [6–8,17,18]. As stimulation of dopamine receptors within the accumbens is well known to increase locomotor activity [19,20], it seems plausible that the effects of these various drugs injected into the MR might be mediated through their common effects on dopamine release. We previously explored this possibility with respect to the hyperactivity produced by injections of the GABA<sub>B</sub> agonist muscimol by examining whether the response to this drug could be antagonized by systemic injections of the preferential D<sub>2</sub> dopamine receptor antagonist haloperidol [17]. We found, however, that haloperidol was without significant effect on muscimol-induced hyperactivity, even when the dopamine antagonist was given at doses which, by themselves, produced marked akinesia and catalepsy.

As haloperidol is able to completely antagonize the hyperactivity induced by dopamine releasing agents, these findings suggest that the effects of intra-MR muscimol injections must be largely independent of changes in dopamine release. It is not known, however, whether a similar conclusion holds for the responses seen after injections of other drugs into the MR. In the current study we, therefore, investigated the effects of systemic haloperidol injections on the responses to intra-MR injections of the GABA<sub>B</sub> agonist baclofen, the µ-opioid agonist D-Ala-Gly-MePhe-Gly(ol)-enkephalin (DAMGO), the δ-opioid agonist D-Pen<sup>2</sup>, D-Pen<sup>2</sup>-enkephalin (DPDPE), and the preferential AMPA/kainate receptor antagonist p-bromobenzoyl-piperazine-2,3-dicarboxylate (pBB-PZDA). In order to confirm our previous findings [17], we also examined animals treated with intra-MR muscimol. Finally, in order to compare effects on MR mediated changes in locomotion to those on a response known to be mediated by dopamine receptor stimulation, we examined the effects of haloperidol on the hyperactivity produced by systemic injections of d-amphetamine. The results of these experiments suggest that dopamine is differentially involved in the responses to different drugs injected into the MR.

1. Methods

1.1. Subjects

Subjects were 38 adult, male Sprague-Dawley derived rats weighing 280–320 g obtained from the colony of the University of Illinois at Chicago. Rats were housed individually on a 12:12 h light:dark cycle in wire-mesh cages with food (Purina Lab Chow) and water available ad libitum. Thirty-two animals received intracranial cannulae aimed at the MR, whereas the remaining 6 subjects, who were used to examine the effects of systemic amphetamine, were not operated.

1.2. Surgery

Rats were anesthetized with sodium pentobarbital (50 mg/kg). Using standard aseptic technique, 22-gauge guide cannulae aimed to terminate 2 mm above the center of the MR (AP: −0.3; L:0.0; H:−2.3 mm from the midpoint of the interaural line [21]) were implanted stereotaxically using dental cement and bone screws to secure them to the skull. The cannulae were lowered in the sagittal plane following retraction of the superior sagittal sinus [22]. A 28-gauge stainless steel obturator which extended 0.5 mm beyond the end of the guide cannula was then inserted. Following surgery, sterile penicillin (1 cc/kg, Durapen) was given to all rats. Subjects were allowed 7 days to recover from surgery.

1.3. Drugs

Muscimol (5-(aminomethyl)-isoxazol-3-ol, molecular weight (MW) = 114.1), DAMGO (MW = 513.6), DPDPE (MW = 645.8), amphetamine (MW = 135.2), and haloperidol (MW = 375.9) were obtained from Sigma Chemical Company (St. Louis, MO) and pBB-PZDA (MW = 357.2) and baclofen ([RS]-4-amino-3-(4-chlorophenyl)butanoic acid, MW = 213.7) from Tocris Neuroamin (Essex, England). All compounds were prepared in sterile normal saline except for haloperidol which was prepared in 30% propylene glycol to which was added the minimum amount acetic acid necessary to dissolve the compound.

1.4. Intracranial drug injections

Microinjections were made through a 28-gauge stainless steel injection cannula connected to a motor driven Hamilton microsyringe by fluid filled polyethylene tubing. After the obturator was taken from the guide cannula, an injection cannula was inserted so that its tip extended 2 mm beyond the end of the guide cannula. All injections were made in a volume of 0.5 μl at a rate of 0.25 μl/min. The injection cannula was removed 30 s after completion of the injection. The obturator was then replaced and the subject returned to the test chambers. All subjects were given one “sham injection”, in which no fluid was infused, prior to the start of behavioral testing in order to acclimate them to the procedure.

1.5. Locomotor activity measurement

Locomotor activity was measured in infrared photocell cages measuring 71.5 × 71.5 × 27 cm. Four infra-red photo beams located 3.5 cm above the floor detected horizontal movements. The boxes were painted black and lighting provided by overhead fluorescent light fixtures. All subjects were given a one hour run in the activity boxes on day 7 following surgery to allow for adaptation to the test environment. On test days, rats received systemic (i.p.) injections of either saline or haloperidol, as detailed below, and were placed in the photocell cages for a 1 h habituation period. Animals were then taken from the boxes and given either systemic or intracranial injections, after which they were returned to the test apparatus for a one hour period.

1.6. Experimental design

Rats were divided into 6 experimental groups containing 6–8 subjects each. One of these groups was unoperated and was used to study the effects of haloperidol on amphetamine induced hyperactivity. Subjects in the remaining five groups were prepared with intra-MR cannulae and were used to study the effects of haloperidol on the hyperactivity induced by intra-MR drug injections. Individual groups were tested with either the GABA<sub>B</sub> agonist muscimol (25 ng), the GABA<sub>B</sub> agonist baclofen (62.5 ng), the µ-opioid receptor agonist DAMGO (437 ng), the δ-opioid agonist DPDPE (97.5 μg) or the kainate/quisqualate antagonist pBB-PZDA (2.5 μg). The doses were selected based on previous dose response studies conducted in our laboratory and were expected to produce roughly equivalent levels of hyperactivity. Each rat received four test runs in the activity boxes separated from each other by at least two intervening days. On one of these runs, subjects were injected systemically with saline (1 ml/kg, i.p.) followed, 60 min later, by intra-MR, or, in the case of the amphetamine group, systemic saline. On the remaining three runs, rats received injections of haloperidol (0.2 or 0.4 mg/kg, i.p.), or its vehicle, immediately before placement in the activity boxes. One hour later the animals were briefly removed from the activity boxes and given intracranial injections of the drug to which their group had been assigned, or, in the case of the unoperated animals, of d-amphetamine sulphate (1.5 mg/kg, s.c.). The order of the four test injections was randomized between animals in each group.
1.7. Cannula placement confirmation

At the end of experiment, all operated rats were perfused transcardially, under deep pentobarbital anesthesia (100 mg/kg), with normal saline followed by a 10% formalin solution. The brains were removed from the skulls and stored in fixative for at least 2 weeks after which 64 µm cryostat sections were cut through the sites of the injection cannulae and subsequently stained with cresyl violet to verify the injection locations.

2. Results

2.1. Histology

All cannula placements were located within the central MR at locations similar to those we have documented extensively in previous reports [6,17,23]. An example of a typical cannula placement is shown in Fig. 1.

2.2. Effects of haloperidol on baseline locomotor activity

Fig. 2 shows that haloperidol treatment produced a suppression of locomotor activity in rats with MR cannulae in the 60 min period preceding intra-MR drug injections. A 3 × 5 (haloperidol dose × intra-MR drug group) ANOVA indicated a significant effect of haloperidol treatment ($F_{(2,54)} = 208.3, p < 0.001$) but differences between the different MR treatment groups were not significant ($p > 0.05$). Haloperidol, thus, produced a similar reduction in spontaneous locomotion in all of the groups with MR cannulae. Fig. 2 also shows that haloperidol suppressed activity during the baseline period in the unoperated animals who were to later receive systemic amphetamine injections ($F_{(2,10)} = 37.4, p < 0.001$). Baseline activity in the absence of haloperidol (i.e., after systemic saline injections) tended to be lower in these unoperated animals than in the groups of animals with intra-MR cannulae and a comparison between unoperated animals and the remaining subjects, collapsed across groups, was significant ($F_{(1,36)} = 11.1, p < 0.002$).

2.3. Effects of haloperidol on locomotor activity induced by intra-MR drug injections

Locomotor activity in the 60 min period following intra-MR drug injections is shown in Fig. 3, where it can be seen that, in the absence of haloperidol, all of the intra-MR drug injections produced marked hyperactivity compared to locomotion following intra-MR saline injections, shown in the bar graphs on the left of the figure. An ANOVA indicated that the increase in locomotor activity over saline did not differ significantly between the 5 MR injection groups in the absence of haloperidol ($p > 0.1$). Examination of Fig. 3 suggests that haloperidol was able to suppress the hyperactivity induced by intra-MR injections of the opioid agonists DPDPE and DAMGO, but had little apparent effect on the response to muscimol, baclofen, or pBB-PZDA. These data were analyzed by means of a 3 × 5 (haloperidol dose × intra-MR drug group) ANOVA with repeated measures...
on the first factor. This analysis indicated a significant treatment X group interaction \( F(8,54) = 2.77, p < 0.012 \) implying that haloperidol differentially affected the responses produced by different drug injections. In order to further clarify the nature of the interaction effect, individual one-way ANOVAs were conducted for each of the 5 intra-MR drug treatments across the three haloperidol dose levels. The Bonferroni correction was applied to the resulting \( p \) values. These results indicated that haloperidol significantly attenuated the responses to DPDPPE \( (F_{2,14} = 36.4, p < 0.005, \) and DAMGO \( (F_{2,10} = 9.63, p < 0.025 \) but not those to muscimol, baclofen, or pBB-PZDA \( F < 1 \) in all cases).

2.4. Effects of haloperidol in rats treated with amphetamine

The bar graphs on the left of Fig. 3 show that the locomotion following systemic saline injections tended to be lower than that seen after intra-MR saline injections \( (F_{1,30} = 12.3, p < 0.001, \) comparing saline to the pooled subjects in the remaining groups), but the locomotor activity produced by amphetamine was similar to that seen after the various intra-MR drug treatments. A one-way ANOVA indicated that the response to amphetamine was significantly attenuated by haloperidol pretreatment \( (F_{2,10} = 69.4, p < 0.001). \)

3. Discussion

The current experiments confirm that the MR exerts a major influence on locomotor activity; even the minor damage produced by cannula insertion appeared to be associated with a significant increase in locomotion relative to unoperated subjects. Much larger increases, however, could be produced by intra-MR injections of drugs acting at a number of different neurotransmitter receptors. The most important result of the current study is that the ability of the preferential \( D_2 \) dopamine receptor antagonist haloperidol to suppress the response to these injections varied depending on the identity of the drug infused into the MR. Thus, haloperidol was able to abolish the hyperactivity induced by intra-MR injections of the opioid agonists DAMGO and DPDPPE, but had little effect on the locomotor responses to the GABA\(_A\) agonist muscimol, the GABA\(_B\) agonist baclofen or the preferential non-NMDA glutamate antagonist pBB-PZDA. In contrast to its differential effects on drug induced activity in the various intra-MR treatment groups, haloperidol produced an equivalent reduction of locomotion in all of the cannulated groups during the baseline period before intra-MR injections. These findings indicate that the MR region must contain multiple mechanisms capable of influencing locomotor activity, some of which are dependent on dopamine, whereas others are not.

The findings of marked hyperactivity following injections of muscimol, baclofen, and pBB-PZDA into the MR are in agreement with previous reports [6,8,9,24], and support the view that the MR exerts an inhibitory effect on behavioral arousal mechanisms. In the case of muscimol and baclofen, much larger effects on activity are seen when the drugs are injected into the MR than at adjacent sites such as the dorsal raphe nucleus (DR) or caudal VTA, suggesting these drugs are acting in the immediate vicinity of the MR [8,11]. Although mapping studies have not been conducted with pBB-PZDA, responses to a number of other glutamate antagonists have similarly been shown to be selective to the MR [6]. The concept that the MR plays a major role in the control of locomotor activity is consistent with reports that lesions of the MR produce much larger increases in locomotion than are seen after lesions of the adjacent DR [1–3]. A great deal of evidence suggests that the effects of both lesions and drug injections are not due primarily to alterations in serotonergic activity [2,9,10,13,25]. Although most workers have focused on the population of serotonin neurons found in the MR, these cells in fact make up a minority of the neurons in this area, and MR cells have been identified which synthesize a variety of other transmitters, including GABA and glutamate [12,26–28]. While the effects of muscimol and pBB-PZDA are likely to be mediated through an action on postsynaptic receptors, it is possible that the effects of baclofen are primarily presynaptic [29].

In addition to increasing locomotion, it has been shown that intra-MR muscimol, baclofen, and glutamate antagonists are all able to increase dopamine metabolism in the nucleus accumbens [6,8,17,18]. As dopamine receptor stimulation in this region is able to increase activity [19,20], a plausible hypothesis is that injections of these drugs into the MR produce hyperactivity as a result of increases in accumbens dopamine release. In the case of muscimol, however, previous studies have provided strong evidence against this theory by demonstrating that the locomotor response to this drug is unaffected by high doses of the \( D_2 \) antagonist haloperidol [17]. The current study, confirms this finding by demonstrating that haloperidol, at doses which totally abolish amphetamine-induced hyperactivity, is without significant effect on the response to muscimol. Additionally, the current results show for the first time that the locomotor responses to both baclofen and pBB-PZDA are similarly independent of \( D_2 \) receptor stimulation. It is striking that the behavioral effects of muscimol, baclofen, and glutamate antagonists are very similar; for example, in addition to hyperactivity they all stimulate pronounced increases in food and water intake [23,30,31] and support self administration [32,33]. These findings further suggest that these drugs are acting on a common substrate. It is possible that the cell populations responsible for hyperactivity are either located downstream from dopaminergic mechanisms, or are components of a behavioral arousal system which is organized in parallel to dopaminergic pathways. In other studies (in preparation) we have found that stimulation of the lateral hypothalamus (LH) also gives rise to dopamine independent hyperactivity; this observation seems of special interest as the MR and LH are heavily interconnected and several lines of evidence suggest that some effects of MR manipulations may be mediated through the LH [30]. Even though \( D_2 \) dopamine receptors may not play an essential role in the locomotor responses to certain drugs injected in the MR, it is possible that they may be involved in other actions of these drugs, such as their rewarding effects as assessed in self administration and conditioned place preference paradigms [32,33,55].

The ineffectiveness of haloperidol is especially striking because it indicates not only that the hyperactivity induced by these drugs does not result entirely from \( D_2 \) receptor stimulation, but that these agents are actually able to overcome the akinesia otherwise induced by \( D_2 \) receptor blockade. It is possible that inhibition of MR cells may in some way antagonize or disengage the mechanisms through which haloperidol suppresses locomotion. Clinical precedents exist for such a possibility; it has, for example, been suggested that parkinsonian motor signs disappear during REM sleep in patients with REM sleep behavior disorder, allowing these individuals to generate movements which would not be possible during normal waking [34]. It is also of interest that selective inhibition of serotonergic cells in the MR, a protocol which has only minor effects on locomotion, is able to antagonize haloperidol induced catalepsy [35]. It is possible that serotonin may be involved in reversing the akinetic effects of haloperidol, even if this transmitter does not play a major role in mediating the locomotor response to MR manipulations. Baclofen injections, however, do not appear to alter hippocampal serotonin release [8,36], even though GABA\(_B\) receptors have been demonstrated on serotonin cells in the MR [29]. (Paradoxical effects of baclofen on serotonin release have also been observed in the DR, and have been suggested to result from presynaptic inhibition of GABA release [37,38]). These findings suggest that serotonin antagonism may not be essential for reversing
haloperidol akinesia; it is possible, however, that baclofen affects serotonin release at sites other than the hippocampus, or that the effects of this drug on serotonin may have been difficult to detect with the methods employed in those studies.

The current findings raise the possibility that effects on dopamine turnover may be mediated through a different cell population than that involved in effects on locomotor activity. Substantial further work will be needed to evaluate this possibility and identify the neurons responsible for these two effects and to determine whether their anatomical distributions are identical.

The present results confirm reports of hyperactivity following intra-MR injection of µ-opioid agonists [7,39] but demonstrate that, in sharp contrast to the results obtained after injections of GABA agonists and EAA antagonists, the response to DAMGO is highly sensitive to haloperidol. As DAMGO injections have been shown to increase dopamine metabolism within the accumbens [7], this finding suggests that the hyperactivity induced by this treatment may be secondary to alterations in dopamine release. These results indicate that the cell populations underlying the effects of DAMGO are not identical to those underlying the responses to GABA agonists and EAA antagonists. This possibility is supported by the fact that a number of differences are present between the effects of DAMGO and those of drugs acting on GABA or glutamate receptors. Intra-MR DAMGO, for example, does not stimulate food intake to nearly the extent as do GABA_A or GABA_B agonists or glutamate antagonists [7]. Unlike muscimol and glutamate antagonists, activation of MR µ-opiate receptors does not alter serotonin metabolism in either the hippocampus or the MR itself [7,39–41]. Perhaps most important, equivalent increases in locomotor activity are seen when DAMGO is injected into either the MR or the far caudal VTA [7]. In contrast, GABA_A and GABA_B agonists and glutamate antagonists produce much larger responses when injected into the MR as opposed to the caudal portions of the VTA [6,8,11].

While it is possible that different cell populations may mediate the effects of DAMGO injected into these two regions, it is also possible that a single µ-opioid sensitive cell population may extend from the region of the MR into the vicinity of the caudal VTA and be affected by DAMGO injections at either site. An especially interesting possible candidate in this regard is the cell group which has been variously referred to as the juxtamedial cell group, the tail of the ventral tegmental area, or the rostromedial tegmental nucleus (RMTg), that lies on the lateral borders of the rostral MR and extends into the lateral portion of the caudal VTA [42–45]. This region contains GABAergic cells, is rich in opioid receptors, and has been shown to project to dopamine cells in the VTA and substantia nigra pars compacta [42,46]. Further studies will be needed to evaluate the involvement of this cell group in the response to µ-opioid agonists. However, it should be noted that many µ-opioid receptor expressing cells are found within the MR itself [47,48] and that the injection sites studied here were located well caudal to the bulk of RMTg cells.

The current data also demonstrate that blockade of D_2 receptors is able to antagonize the hyperactivity induced by intra-MR injections of the δ-opioid agonist DPDPE [7]. As intra-MR injections of this compound have been shown to increase dopamine metabolism in both the nucleus accumbens and the dorsal striatum [7], it is again plausible that these locomotor effects may be secondary to alterations in dopamine release. δ-opioid receptors have been shown to be present within the MR [49–51] and previous studies have demonstrated that DPDPE is much more effective at inducing hyperactivity when injected into the MR than the caudal VTA [7]. These results suggest that the hyperactivity induced by DPDPE is unlikely to be mediated through diffusion to the RMTg and, thus, indicate that dopamine dependent hyperactivity can be obtained from the MR itself. In previous studies we have found that DPDPE injections do produce a small decrease in hippocampal serotonin metabolism but, unlike drugs acting on GABA or glutamate transmission, appear unable to alter food or water intake [7]. Thus, the behavioral profile of DPDPE differs from that of the agents which produce dopamine-insensitive hyperactivity, further indicating that the substrate of DPDPE’s effects cannot be identical to that of GABAergic and glutamatergic agents.

In summary, the current results support two major conclusions. First, they strongly indicate that the MR region contains a substrate which is capable of exerting a powerful influence over behavioral arousal that is independent of D_2 dopamine receptor stimulation. It is likely that the cell population that underlies this effect plays an important, and underappreciated, role in the control of behavioral activation. As the MR region receives heavy afferent projections from the prefrontal cortex and a number of hypothalamic sites [52–54], it may play a role in mediating the influence of these structures on behavioral activation. Given the ability of certain agents in the MR to overcome effects of dopamine blockade, it is possible that pharmacological manipulation of this system might be of therapeutic relevance in parkinsonian syndromes. Second, our results, together with those of previous studies, demonstrate that different drugs injected into the MR produce different patterns of behavioral and neurochemical effects, suggesting that the paramedian tegmentum must contain multiple cell populations that differentially influence behavior and neural activity. Given the powerful and ubiquitous nature of the responses produced by manipulations of this region, it seems that a detailed characterization of the neural circuitry of the region is likely to substantially advance our understanding of the mechanisms underlying behavioral arousal.

Acknowledgements

Supported in part by NIH grants R03DA020802 and R01DK071738. IS was supported by the 2013 research leave program grant from Kyung Hee University.

References


[31] Fletcher PJ. Effects of 8-OH-DPAT, 5-CT and muscimol on behavior maintained by a DRL20 schedule of reinforcement, following microinjection into the dorsal or median raphe nuclei. Behav Pharmacol 1994;5:326–36.


